Brief: Journey Medical Corp Completes Enrollment In Phase 3 Clinical Trials Evaluating Dfd-29 (Minocycline Modified Release Capsules 40 Mg) For Treatment Of Papulopustular Rosacea
10/01/2023 13:31
Jan 10 (Reuters) - Journey Medical Corp DERM.O :
* JOURNEY MEDICAL CORPORATION COMPLETES ENROLLMENT IN PHASE
3
CLINICAL TRIALS EVALUATING DFD-29 (MINOCYCLINE MODIFIED RELEASE
CAPSULES 40 MG) FOR TREATMENT OF PAPULOPUSTULAR ROSACEA
Source text for Eikon: ID:nGNX3hkPNS
Further company coverage: DERM.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Journey Medical
See all newsJourney Medical Corp expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
U.S. STOCKS ON THE MOVE-Five Below, Salesforce, IBM, Akamai Technologies